Increased Serum Levels of Eotaxin in Patients with Inflammatory Bowel Disease

2001 ◽  
Vol 36 (5) ◽  
pp. 515-520 ◽  
Author(s):  
W. Chen, B. Paulus, D. Shu, I. Wils
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Inflammatory Bowel

Positive Association between Leptin Serum Levels and Endoscopic Activity in Inflammatory Bowel Disease

2017 ◽  
Vol 152 (5) ◽  
pp. S766
Author(s):  
Fabiola Trejo-Vazquez ◽  
Idalia Garza-Veloz ◽  
Alejandra Villela-Ramirez ◽  
panfilo Mauricio-Saucedo ◽  
Yolanda Ortiz Castro ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Positive Association ◽  
Serum Levels ◽  
Inflammatory Bowel

scholarly journals P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S171-S171
Author(s):  
M. Chaparro ◽  
M. Barreiro-de Acosta ◽  
A. Echarri ◽  
R. Almendros ◽  
J. Barrio ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Mucosal Healing ◽  
Inflammatory Bowel

scholarly journals Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease

2019 ◽  
Vol 37 (6) ◽  
pp. 444-450 ◽  
Author(s):  
Joaquín Hinojosa ◽  
Fernando Muñoz ◽  
Gregorio Juan Martínez-Romero
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Outcome ◽  
Maintenance Therapy ◽  
Bowel Disease ◽  
Clinical Remission ◽  
Meta Analysis ◽  
Serum Levels ◽  
Mucosal Healing ◽  
Endoscopic Remission ◽  
Inflammatory Bowel

Background: Adalimumab (ADA) is an anti-tumor necrosis factor agent that has been shown to be effective in inducing and maintaining remission in adult patients with inflammatory bowel disease. The relationship between the ADA trough levels and clinical efficacy has been demonstrated, but there is variability in the definition of the most suitable range for its clinical applicability. Summary: A review of published studies during the last 5 years on ADA serum levels and its relationship with the clinical outcome was performed. The studies selected included 7 observational studies, a systematic review, a meta-analysis and a post hoc analysis of a clinical trial. The reported ADA levels that discriminate patients in clinical remission from those with active disease range from 4.5 to 8 µg/mL. This therapeutic range varies when considering endoscopic remission (7.5 to >13.9 µg/mL). Although the sample of patients with ulcerative colitis is small, a tendency to reach higher levels of ADA is observed in both clinical and endoscopic remission. Key Messages: The optimal therapeutic cut-off point of serum ADA levels ranges from 4.5–5 to 12 µg/mL, where ADA levels are associated with an adequate clinical monitoring of the disease during maintenance therapy. These ranges vary according to the target, suggesting levels of 4.8 µg/mL as the cut-off for clinical remission and levels ≥7.5 µg/mL for mucosal healing/endoscopic response. Controlled prospective studies are required to determine the optimal therapeutic interval of ADA serum levels both as induction and as maintenance therapy.

Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease

2011 ◽  
Vol 17 (4) ◽  
pp. 963-970 ◽  
Author(s):  
Konstantinos A. Oikonomou ◽  
Andreas N. Kapsoritakis ◽  
Anastasia I. Kapsoritaki ◽  
Anastassios C. Manolakis ◽  
Elisavet K. Tiaka ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Inflammatory Bowel ◽  
Angiopoietin 2 ◽  
Angiopoietin 1

741 Low Serum Levels of IgG4 Antibodies May Function as a Biomarker of Severity in Inflammatory Bowel Disease

2019 ◽  
Vol 114 (1) ◽  
pp. S435-S436
Author(s):  
Filippos Koutroumpakis ◽  
Anna E. Philipps ◽  
Dhiraj Yadav ◽  
Claudia Ramos Rivers ◽  
Marc Schwartz ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Inflammatory Bowel ◽  
Low Serum

scholarly journals Imbalance of tissue inhibitors of metalloproteinases (TIMP) – 1 and – 4 serum levels, in patients with inflammatory bowel disease

2008 ◽  
Vol 8 (1) ◽  
Author(s):  
Andreas N Kapsoritakis ◽  
Anastasia I Kapsoritaki ◽  
Ioanna P Davidi ◽  
Vasilios D Lotis ◽  
Anastasios C Manolakis ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Tissue Inhibitors Of Metalloproteinases ◽  
Tissue Inhibitors ◽  
Inflammatory Bowel

scholarly journals An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Zehra Betül Paköz ◽  
Cem Çekiç ◽  
Mahmut Arabul ◽  
Elif Sarıtaş Yüksel ◽  
Serkan İpek ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Active Phase ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Inflammatory Bowel ◽  
The Mean

Aim. While there are many well-defined serological markers for inflammatory bowel disease (IBD), there is limited evidence that they positively affect clinical outcomes. This study aimed to evaluate the correlation between hepcidin serum levels and disease activity in IBD.Materials and Methods. Eighty-five consecutive IBD patients were enrolled in the study. Hepcidin serum levels were assessed using an enzyme-linked immunosorbent assay (ELISA) and were compared with disease activity as well as the interleukin-6 (IL-6) and C-reactive protein (CRP) levels.Results. The mean hepcidin serum levels in Crohn’s disease (CD) patients in remission and in the active phase were3837±1436and3752±1274 pg/mL, respectivelyP=0.613. The mean hepcidin serum levels in ulcerative colitis (UC) patients in remission and in the active phase were4285±8623and3727±1176 pg/mL, respectivelyP=0.241. Correlation analysis between inflammatory markers and hepcidin serum levels indicated that there was no correlation between hepcidin levels and IL-6P=0.582or CRPP=0.783.Conclusion. As an acute-phase protein, hepcidin seems to have a lower efficacy than other parameters in the detection of activation in IBD.

Sign in / Sign up

Export Citation Format

Share Document